FDA Approves 1st Treatment for Niemann-Pick Disease, Type C
Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...
While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...
Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...
Health on MSN3d
Does Adjuvant Therapy Prevent Cancer Recurrence?"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...
The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...
They were pleading for “access - not excuses” when it came to Genentech’s promising new treatment for metastatic breast cancer: a drug called trastuzumab, also known as Herceptin®.
High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or ...
Cell and gene therapy: Dr. Jeff Hersh examines 25 years of technological advances In general, earlier stage cancers have ...
HER2-positive breast cancers can be very aggressive. For several years, the drug Herceptin has been used to treat women with HER2-positive breast cancer that has metastasized or recurred.
If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Herceptin SC? Herceptin SC contains the active ingredient trastuzumab. Herceptin SC is used to ...
A 22-year-old LASU student is urgently seeking N15 million financial assistance as she battles an aggressive form of breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback